{
    "id": 27579,
    "cites": 44,
    "cited_by": 0,
    "reference": [
        "Acemoglu, Daron, and Joshua Linn. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 119(3):1049-1090.",
        "Amin, Tahir, and Aaron S. Kesselheim. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Secondary Patenting of Branded Pharmaceuticals: A Case Study of How Patents on Two HIV Drugs Could be Extended for Decades,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 31 (10): 2286-2294.",
        "Berndt, Ernst R., and Joseph P. Newhouse. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing and Reimbursement in US Pharmaceutical Markets.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Patricia M. Danzon and Sean Nicholson, 201\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c65. NewYork: Oxford University Press.",
        "Berndt, Ernst R., Deanna Nass, Michael Kleinrock, and Murray Aitken. 2015. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Decline inEconomic Returns from New Drugs Raises Questions about Sustaining Innovations,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 34 (2): 245\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c52.",
        "Berndt, ER, RM Conti, and SJ Murphy. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Landscape of US Generic Prescription Drug Markets, 2004\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2016,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper No. w23640.",
        "Besanko, David, David Dranove, and Craigh Garthwaite. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Insurance and the High Prices of Pharmaceuticals,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper 22353.",
        "Bognar, Katalin, John Romley, Jay Bae, James Murray, Jacquelyn Chou and Darius N. Lakdawalla. 2017. The Role of Imperfect Surrogate Endpoint Information in Drug Approval and Reimbursement Decisions, Journal of Health Economics 51: 1-12.",
        "Branstetter, Lee, Chirantan Chatterjee, and Matthew Higgins. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics 47(4): 857-890.",
        "Budish, Eric H., Benjamin H. Roin, and Heide Williams. 2015. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Firms Underinvest in Long Term Research? Evidence from Cancer Clinical Trials.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 105 (7): 2044\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c85 Cameron, A. Colin, Jonah G. Gelbach, and Douglas L. Miller. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Robust Inference with MultiWay Clustering.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal Business and Economic Statistics 29(2): 238-249.",
        "Cohen, Wesley M., Richard R. Nelson, and Joseph P. Walsh. 2000. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Protecting Their Intellectual Property Rights: Appropriability Conditions and Why U.S. Manufacturing Firms Patent or Not.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper No. 7552.",
        "Conti, RM, and ER Berndt. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Specialty Drug Prices and Utilization after Loss of US Patent Exclusivity, 2001\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2007.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper No. 20016.",
        "Danzon, Patricia, and Li-Wei Chao. 2000. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Does Regulation Drive Out Competition in Pharmaceutical Markets?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 43(2): 311-357.",
        "de Ree, Joppe, and Rob Alessie, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Life Satisfaction and Age: Dealing with Underidentification in Age-Period-Cohort Models,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Social Science and Medicine, 73 (2011), 177\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c82.",
        "DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 47: 20\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c33.",
        "Drake, Keith M., Martha A. Starr, and Thomas McGuire. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do `Reverse Payment\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper 20292.",
        "Dranove, David, Craig Garthwaite, and Manuel Hermosilla. 2020. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Expected Profits and the Scientific Novelty of Innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper w27093 Duggan, Mark, and Fiona Scott Morton. 2010. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization. American Economic Review, 100 (1): 590-607.",
        "Frakes, Michael, and Melissa Wasserman. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Is the Time Allocated to Review Patent Applications Inducing Examiners to Grant Invalid Patents?: Evidence from Micro-Level Application Data\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Review of Economics and Statistics 99(3): 550-563.",
        "Frakes, Michael, and Melissa Wasserman. 2019. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Patent Law Suits Target Invalid Patents?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in SELECTION AND DECISION IN JUDICIAL PROCESS AROUND THE WORLD: EMPIRICAL INQUIRIES, ed. Yun-chien Chang, Cambridge University Press.",
        "Garthwaite, Craig. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Journal: Applied Economics 4(3): 116-37.",
        "Duggan, Mark, and Craig Garthwaite. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Empirical Evidence on the Value of Pharmaceuticals,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in The [Oxford] Handbook of the Economics of the Biopharmaceutical Industry: Oxford University Press: Oxford: 463-492.",
        "Duggan, Mark, Craig Garthwaite, and Aparajita Goval. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Market Impacts of Product Patents in Developing Countries,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 106(1): 99-135 Giaccotto, Carmelo, Rexford Santerre and John Vernon. 2005. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 48(1): 195-214.",
        "Goldman, Dana P., Darious N. Lakdawalla, Jessie D. Malkin, John Romley, and Thomas Philipson. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Benefits from Giving Makers of Conventional \u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009cSmall Molecule\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Drugs Longer Exclusivity Over Clinical Trial Data.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 30 (1): 84\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c90 Grabowski, Henry, Carlos Brain, Anna Taub, and Rahul Guha, 2017. Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes, American Journal of Health Economics 3(1): 33-59.",
        "Grabowski, Henry, and John Vernon. 1992. Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Drug Act,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 35(2): 331-350.",
        "Helland, Eric, and Seth Seabury. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper 22194.",
        "Hall, B. H., A. Jaffe, and M. Trajtenberg. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The NBER Patent Citations Data File: Lessons, Insights and Methodological Tools,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper 8498.",
        "Hemphill, C. Scott, and Bhaven N. Sampat. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Evergreening, patent challenges, and effective market life in pharmaceuticals,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 31: 327-339.",
        "Henderson, Rebecca, and Iain Cockburn. 1996. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics 28: 32\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c59.",
        "Higgins, Matthew J., and Stuart J. H. Graham. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Balancing Innovation and Access: Patent Challenges Tip the Scale.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science 326 (5951): 370\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c71.",
        "IMS Institute for Healthcare Informatics. 2016. Price Declines after Branded Medicines Lose Exclusivity in the U.S. Jena AB, Calfee J, Mansley E, Philipson TJ. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Me-too innovation in pharmaceutical markets,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics & Policy 12(1).",
        "Joyce, Geoffrey F., and Neeraj Sood. 2016.\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Why Medicare Price Negotiation is the Wrong Prescription for Rising Drug Spending.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Policy Analysis and Management 35(4): 956-963.",
        "Kapczynski, Amy, Chan Park, and Bhaven N. Sampat. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Hydrates and Solvates and Salts (oh my!): Secondary Patents in Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d PloS ONE, 12 December.",
        "Kolstad, C. D., Ulen, T. S., and Johnson, G. V. 1990. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Ex Post Liability for Harm vs. Ex Ante Safety Regulation: Substitutes or Complements?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 80(4): 888\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c901.",
        "Lakdawalla, Darius, and Tomas Philipson. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 55(1): 151-187.",
        "Lakdawalla, Darius and Neeraj Sood. 2009. Innovation and the Welfare Effects of Public Drug Insurance. Journal of Public Economics 93(3-4): 541-548.",
        "Nicholson, Sean, 2012, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Financing Research and Development,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Patricia M. Danzon and Sean Nicholson. Oxford University Press.",
        "Lei, Zhen, and Brian D. Wright. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Why Weak Patents? Testing the Examiner Ignorance Hypothesis,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 148: 43-56.",
        "Lemley, Mark A.. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Rational Ignorance at the Patent Office,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Northwestern University Law Review: 1495\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1532.",
        "Nordhaus, William, Invention, Growth, and Welfare (Cambridge, MA: MIT Press, 1969).",
        "Panattoni, Laura E. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Paragraph IV Decisions and Generic Entry BeforePatent Expiration on Brand Pharmaceutical Firms.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 30(1): 126\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c45 Picard, Pierre M., and Bruno van Pottelsberghe de la Potterie. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent Office Governance and Patent System Quality,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 104(14).",
        "Righi, Cesare, and Timothy Simcoe, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent Examiner Specialization,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo (2017).",
        "Sampat, Bhaven, and Kenneth Shadlen. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Secondary pharmaceutical patenting: A global perspective,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Research Policy 46(3): 693-707.",
        "Sampat, Bhaven, and Heidi Williams. 2019. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How Do Patents Affect Follow-on Innovation? Evidence from the Human Genome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 109(1): 203-36.",
        "F.M. Scherer, 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Political Economy of Patent Policy Reform in the United States\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d (Dynamics of Insts. & Mkts. in Eur., Intellectual Prop. Rights Working Paper No. 26, 2006), Scott Morton, Fiona M. 1999. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Entry Decisions in the Generic Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics 30(3): 421-440.",
        "Shavell, Steven. 1984. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Liability for Harm Versus Regulation of Safety.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Legal Studies 13(2): 357-74. FIGURE I. COVARIATE-BALANCE ANALYSIS: RELATIONSHIP BETWEEN PREDICTED LIKELIHOOD OF EPO ALLOWANCE OF TWIN OF U.S.-ISSUED ORANGE BOOK PATENT AND GRADE-LEVEL OF EXAMINER ASSIGNED TO RELEVANT U.S. PATENT"
    ]
}